Medidata Solutions, Inc.

LONDON--( BUSINESS WIRE )-- Medidata , a Dassault Systèmes brand and leading provider of clinical trial solutions to the life sciences industry, and the European Organisation for Research and Treatment of Cancer (EORTC), announced today a four-year extension to their partnership. The extended relationship will enable EORTC to further increase patient access to oncology clinical trials, make trial participation easier, and help to deliver new treatments to the market faster. EORTC is now leveraging 13 Medidata solutions, enabling their researchers to access and manage all clinical data in a single place and offering patients a seamless trial experience. Vassilis Golfinopoulos, headquarters director, EORTC, said, “We chose the Medidata Platform to further expand our data management and patient engagement capabilities based on our years of experience working together. This partnership will enhance our support for oncology researchers as we collaborate on innovative ways of working with clinical trial data in the future.” “This expansion benefits patients through an improved clinical trial experience, engaging with study activities on their personal mobile devices, while researchers will have the ability to make better decisions faster,” said Janet Butler, executive vice president, head of global sales, Medidata. “The integration of additional solutions, including Medidata Rave CTMS and Medidata Rave eTMF , will empower EORTC researchers with higher data quality, allowing them to shorten study timelines and deliver safer oncology trials for patients.” For EORTC the expanded partnership also allows the exploration of a joint research and data collaboration with Medidata AI solutions in pursuit of improved standards of cancer care. About Medidata Medidata is powering smarter treatments and healthier people through digital solutions to support clinical trials. Celebrating 25 years of ground-breaking technological innovation across more than 34,000 trials and 10 million patients, Medidata offers industry-leading expertise, analytics-powered insights, and the largest patient-level historical clinical trial data set in the world. More than 1 million registered users across approximately 2,200 customers trust Medidata’s seamless, end-to-end platform to improve patient experiences, accelerate clinical breakthroughs, and bring therapies to market faster. A Dassault Systèmes brand (Euronext Paris: FR0014003TT8, DSY.PA), Medidata is headquartered in New York City and has been recognized as a Leader by Everest Group and IDC. Discover more at www.medidata.com and follow us @Medidata. About Dassault Systèmes Dassault Systèmes is a catalyst for human progress. We provide business and people with collaborative virtual environments to imagine sustainable innovations. By creating virtual twin experiences of the real world with our 3DEXPERIENCE platform and applications, our customers can redefine the creation, production and life-cycle-management processes of their offer and thus have a meaningful impact to make the world more sustainable. The beauty of the Experience Economy is that it is a human-centered economy for the benefit of all – consumers, patients and citizens. Dassault Systèmes brings value to more than 350,000 customers of all sizes, in all industries, in more than 150 countries. For more information, visit www.3ds.com © Dassault Systèmes. All rights reserved. 3DEXPERIENCE, the 3DS logo, the Compass icon, IFWE, 3DEXCITE, 3DVIA, BIOVIA, CATIA, CENTRIC PLM, DELMIA, ENOVIA, GEOVIA, MEDIDATA, NETVIBES, OUTSCALE, SIMULIA and SOLIDWORKS are commercial trademarks or registered trademarks of Dassault Systèmes, a European company (Societas Europaea) incorporated under French law, and registered with the Versailles trade and companies registry under number 322 306 440, or its subsidiaries in the United States and/or other countries. All other trademarks are owned by their respective owners. Use of any Dassault Systèmes or its subsidiaries trademarks is subject to their express written approval.

The four-year extension focuses heavily on enhancing data management in oncology research, allowing EORTC to streamline patient access to clinical trials and optimize trial participation while leveraging a single platform for comprehensive data handling. As clinical trials increasingly generate vast amounts of complex data, EORTC is now utilizing 13 Medidata solutions to manage all trial data in one place. This integration not only simplifies the clinical trial process for researchers but also improves data accuracy, quality, and accessibility—key components for driving the next phase of oncology research. Vassilis Golfinopoulos, headquarters director at EORTC, emphasized the critical role of this collaboration. She said: “We chose the Medidata Platform to further expand our data management and patient engagement capabilities based on our years of experience working together. This partnership will enhance our support for oncology researchers as we collaborate on innovative ways of working with clinical trial data in the future.” Tracking patient outcomes The extended partnership places a strong emphasis on centralizing clinical data management, helping researchers and clinicians streamline processes that were previously time-consuming and disjointed. By consolidating clinical trial data into one accessible platform, EORTC is improving its ability to track patient outcomes, optimize trial operations, and, ultimately, accelerate the timeline from study inception to treatment delivery. One of the most significant advancements of this partnership is the implementation of Medidata Rave CTMS (Clinical Trial Management System) and Medidata Rave eTMF (electronic Trial Master File). These tools provide EORTC with powerful capabilities to manage, track, and report on trial data with higher precision. By offering a single, unified system for data collection and analysis, these solutions will streamline administrative tasks, allowing researchers to focus more on clinical insights and decision-making. googletag.cmd.push(function () { googletag.display('text-ad1'); }); Janet Butler, executive vice president and head of global sales at Medidata, highlighted the impact of these integrated data solutions and said: “This expansion benefits patients through an improved clinical trial experience, engaging with study activities on their personal mobile devices, while researchers will have the ability to make better decisions faster. The integration of additional solutions, including Medidata Rave CTMS and Medidata Rave eTMF, will empower EORTC researchers with higher data quality, allowing them to shorten study timelines and deliver safer oncology trials for patients.” Vast amounts of clinical data For EORTC, high-quality, well-managed data is crucial for optimizing the patient experience and improving clinical trial outcomes. Medidata's platform offers real-time insights and rigorous data governance, ensuring that every stage of a clinical trial is backed by reliable, actionable information. By centralizing data operations, EORTC can minimize discrepancies, reduce delays, and accelerate the development of life-saving treatments for cancer patients. The extended partnership also allows for a joint exploration of research and data collaboration opportunities through Medidata’s AI solutions. Leveraging artificial intelligence will further enhance EORTC’s ability to manage and interpret vast amounts of clinical data, helping researchers identify patterns and make informed decisions faster. This partnership extension between EORTC and Medidata signifies a transformative shift in how oncology research handles data. By focusing on streamlining data management processes, the collaboration aims to improve the overall efficiency of cancer trials and contribute to faster, safer treatment development. This alignment of technological innovation with clinical research expertise sets a new benchmark for oncology trials, where robust data handling is key to improving patient outcomes.

With Medidata’s platform, Aixial will create what’s known as a single source of truth, meaning that the company’s data will be accessible from one digital location. France-based clinical research company Aixial Group is consolidating clinical data from one of its business units into Medidata’s digital platform, according to a Sept. 3 release.The partnership will allow Aixial to support patient data privacy, monitor throughout studies and make better-informed decisions, the release said.Aixial works with trial sponsors to develop oncology, cell and gene, and rare disease therapies. “Consolidating clinical data onto the Medidata Platform will power the experience and expertise of our teams to deliver this superior service for our customers,” Aixial Chief Technology Officer Tim Corbett-Clark said in the release. By bringing data into Medidata’s platform, Aixial will create what’s known as a single source of truth, meaning that the company’s data will be accessible from one digital location. Having data readily available in a single place can speed up decision-making and improve cybersecurity.Medidata also had another buyer for its technology recently: Japanese Big Pharma Eisai. In that partnership, Eisai is incorporating Medidata’s data studio into its own clinical trial management platform.